Instrument Inactif

Communiqués Threshold Pharmaceuticals, Inc. Nasdaq

Actions

US8858072064

Recherche biotechnologique et médicale

Communiqués

19/12/24	Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules	AQ
04/12/24	Molecular Templates : Proxy Results Form 8 K	PU
04/12/24	Molecular Templates : Management Change/Compensation Form 8 K	PU
02/12/24	Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements	AQ
11/10/24	Molecular Templates : Reorganization Form 8 K	PU
04/10/24	Molecular Templates : Reorganization Form 8 K	PU
14/08/24	Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update	AQ
03/06/24	Molecular Templates, Inc. Provides Interim Update	AQ
15/05/24	Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update	AQ
09/04/24	Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism	AQ
29/03/24	Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update	AQ
28/03/24	Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement	AQ
04/03/24	Molecular Templates, Inc. Provides Interim Update	AQ
08/02/24	Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	AQ
13/11/23	Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update	AQ
02/11/23	Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	AQ
01/11/23	Molecular Templates to Participate in Upcoming Investor Conferences	AQ
28/09/23	Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer	AQ
11/08/23	Molecular Templates Announces 1-for-15 Reverse Stock Split	AQ
10/08/23	Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update	AQ
02/08/23	Molecular Templates Announces Executive Leadership Changes	AQ
13/07/23	Molecular Templates Announces Up to $40 Million Private Placement Offering	AQ
20/06/23	MOLECULAR TEMPLATES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/06/23	Molecular Templates Announces Debt Payoff and Restructuring	AQ
17/06/23	Molecular Templates Announces Debt Payoff and Restructuring	AQ